MARK2 and non-small cell lung carcinoma: The mammalian target of rapamycin (mTOR), a serine/threonine kinase existing in two functionally distinct complexes (mTORC1 and mTORC2), is commonly up-regulated in various human cancers including NSCLC [34–37].